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Objectives: Denosumab is a human recombinant monoclonal antibody that has been approved for the
treatment of postmenopausal osteoporosis in women with a high risk of fracture. The antibody binds the
receptor activator of nuclear factor kB ligand, which blocks the maturation, function, and survival of
osteoclasts, and therefore reduces bone resorption. Many patients treated with denosumab for osteo-
porosis have previously received other antiresorptive therapy that may inﬂuence the antiosteoporotic
effect. The aim of this study is to elucidate if transition from raloxifene to denosumab is beneﬁcial in
antiosteoporotic treatment.
Materials and methods: This retrospective study recruited postmenopausal women with bone mineral
density (BMD) T-scores in the lumbar spine (LS) or femoral neck (FN)  2.5 who received regular
treatment with raloxifene or/and denosumab. The patients were divided into three groups. The R group
received oral raloxifene 60 mg daily for at least 24 months. The D group received subcutaneous deno-
sumab 60 mg every 6 months for at least 24 months. The T group received raloxifene for at least 6
months, and then shifted to denosumab for at least 18 months. BMD and renal function were also
evaluated in these patients.
Results: Approximately 60% of patients adhered to the raloxifene regimen and ~95% adhered to the
denosumab regimen. Spine BMD increased less in the T group than in the D group at Month 24. BMD in
the spine and hip increased more in the T group than the R group. There was no deterioration of renal
function or adverse events in any of the three groups.
Conclusion: Patients who transitioned from raloxifene to denosumab showed good adherence with
treatment and signiﬁcant improvement in BMD in the spine and hip without a negative inﬂuence on
renal function. Discussing the characteristics of both drugs and the best antiosteoporotic treatment with
patients is critical for satisfactory results in the prevention of fractures.
Copyright © 2015, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Osteoporosis is a chronic, progressive condition characterized
by decreased bone mass and microarchitectural deterioration. It
causes bone fragility and a signiﬁcantly increased risk of fracturecs, Hualien Tzu Chi Hospital,




elief Tzu Chi Foundation. Publishe[1e3]. More than 75 million people throughout the world are
affected by osteoporosis [4]. The goal of treatment is to alter the
balance of bone remodeling to increase bone mass. Anti-
resorptive agents are the predominant therapy for the preven-
tion and treatment of bone loss. Different medications are given
orally, subcutaneously, or intravenously [5e7]. Several oral drugs
used in the treatment of postmenopausal osteoporosis, which
have all shown efﬁcacy in reducing fracture risk, are greatly
affected by adherence to treatment, a critical issue in the man-
agement of osteoporosis [8,9]. Many patients do not perceive the
need for treatment of osteoporosis until they experience the ﬁrst
fracture [10].d by Elsevier Taiwan LLC. All rights reserved.
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creases in bone mineral density (BMD) by inhibiting the receptor
activator of nuclear factor kB ligand, which is essential for the for-
mation, activity, and survival of osteoclasts [11e15]. In post-
menopausal women with osteoporosis, denosumab 60 mg
administered subcutaneously every 6 months signiﬁcantly reduced
bone turnovermarkers, increased BMD, and reduced new vertebral,
hip, and nonvertebral fractures compared with placebo in a pivotal
36-month fracture trial [16]. In previous studies, denosumab
treatment for up to 4 years signiﬁcantly increased BMD in the
lumbar spine (LS), total hip, distal third of the radius, and total body
compared with placebo [17e20]. Patients who had never been
treated, or had previously been treated with bisphosphonates, who
then transitioned to denosumab treatment had better gains in BMD
and decreased bone turnovermarkers comparedwith patients who
received regular bisphosphonate medication only [21,22]. Raloxi-
fene was ﬁrst approved by the European Union and the United
States Food and Drug Administration for treating and preventing
osteoporosis in postmenopausal women. It is known as a benzo-
thiophene selective estrogen receptor modulator, which partially
mimics the effects of estrogens [23]. The beneﬁcial effects of oste-
oporosis therapy in menopausal women are unclear, especially in
those taking raloxifene or denosumab or transitioning between
these medications.
In addition to improvement in bone density, the renal effects of
antiosteoporotic agents are also a critical issue. As both osteopo-
rosis and renal insufﬁciency become more prevalent with age, it is
important for doctors to understand the effect of medical therapies
in osteoporotic patients with different levels of renal function.
Although a previous study revealed that denosumab seemed to be
safe for patients in all stages of chronic kidney disease [15] and
raloxifene may have a renoprotection effect [23], the renal effect of
transition therapy is still seldom studied.
The current study was conducted in postmenopausal women
previously treated with raloxifene to evaluate the safety, BMD, and
renal function in those transitioning to denosumab in comparison
with those continuing raloxifene therapies.
2. Materials and methods
We performed a retrospective analysis of 2000 female patients
who received regular raloxifene or/and denosumab in the Ortho-
pedic Outpatient Department of Hualien Tzu Chi Hospital, Haulien,
Taiwan from January 2009 to September 2014. Patient data were
reviewed from medical records by an orthopedic surgeon. The pa-
tients were divided into three groups. The R group received oral
raloxifene 60 mg per day for at least 24 months, the D group
received subcutaneous injections of denosumab 60 mg every 6
months for at least 24 months, and the T group received raloxifene
for at least 6 months and then transitioned to denosumab for at
least 18 months. The inclusion criteria were as follows: ambulatory
postmenopausal women at least 55 years of age with BMD mea-
surements in the LS or femoral neck (FN) corresponding to a T-score
of < 2.5, who received regular subcutaneous injections of deno-
sumab 60mg every 6months or oral raloxifene 60mg per day for at
least 6 months. The exclusion criteria were: (1) male patients, (2)
younger than 55 years, (3) postmenopausal period < 5 years, or (4)
previous treatment with other osteoporotic medications, such as
bisphosphonates and teriparatide. Adherence to medication ther-
apywas deﬁned in terms of the ratio of total number of days of drug
administration therapy (based on dispensed prescriptions) be-
tween the accurate prescription date and date of the ﬁrst follow-up
survey to the total number of calendar days between these dates.
We collected the BMD in the LS and FN by dual energy X-ray ab-
sorptiometry and the estimated glomerular ﬁltration rate (eGFR) atbaseline and 24 months after treatment in the R and D groups. In
the T group we collected the BMD data at transition and 24 months
after beginning denosumab treatment. The fracture risk assessment
(FRAX) of these patients was calculated from the site: http://www.
shef.ac.uk/FRAX/tool.jsp?lang¼cht based on Taiwan population
data. We used the BMD percentage change (BMD-PC) as an indi-
cator of improvement in bone density, which was calculated as
follows: (posttherapy absolute BMD e pretherapy absolute BMD)/
pre-therapy absolute BMD. We also collected the T scores of the
patients, which are the values of their BMD compared with the
ideal or peak BMD of healthy 30-year-old adults. The differences in
the worst total spine T score pre/post therapy were also collected
and divided into three stages:  0, 0e0.5, >0.5.The data were used
for analyses. The eGFR was calculated following the formula:
186*Serum creatinine1.154* Age 0.203 (* 0.742 if female).We
collected body mass index (BMI data and divided the patients into
four groups: underweight (BMI < 18.5), normal (18.5  BMI < 24),
overweight (24  BMI < 27), and obese (27  BMI). Fractures after
48 months of treatment were reported as adverse events. The
percentage of adherence to the medication regimen was assessed
by prescription records.
2.1. Statistical analysis
The data were expressed as frequencies, proportions, or
mean ± standard deviations, depending on the characteristics of
each item. The Chi-square test was used to evaluate the association
between two categorical variables. One-way analysis of variance (1-
way ANOVA) was used to compare the differences in means be-
tween different groups. The Bonferroni correction was adopted to
performmultiple comparisons of groupmeanswhenever therewas
a signiﬁcant F test result in ANOVA. Statistically signiﬁcant differ-
ences were deﬁned as p < 0.05. All of the statistical analyses were
performed using SPSS software version 17.0 (SPSS Inc., Chicago, IL,
USA).
3. Results
Among 2,000 cases reviewed, 1615 women enrolled in the
study: 1000 in the R group, 477 in the D group, and 138 in the T
group. The percentages of adherence to the medication regimen
were 65 ± 16%, 98 ± 22%, and 96 ± 32% in these groups, respectively
(Table 1). The adherence in the R group was signiﬁcantly less than
in the D and T groups (p < 0.001).
Of the 1615 women, 134 (8.3%) had complete data for the BMD
and pretherapy and posttherapy eGFR (Table 2), 67 in the R group,
33 in the T group, and 34 in the D group. The mean age in the R
group was lower than that in the T and D groups (p < 0.001). More
women in the D and T groups had hypertension and a history of
vertebroplasty for vertebral compression fracture than in the R
group (p < 0.05). According to the FRAX values, there were signif-
icant differences in the risks of main and hip fractures between
groups with the highest values in the T group, followed by the D
group, with the lowest rate in the R group (p < 0.001).
BMD-PCs in the spine and bilateral hips were signiﬁcantly
greater in the T group than the R group (p < 0.001; Table 3). BMD-
PCs in the spine in the D group were signiﬁcantly higher than those
in T group (p < 0.001). A post hoc test revealed that BMD-PCs in the
spine and bilateral hips were signiﬁcantly higher in the T and D
groups than the R group. There was no difference between the T
and D groups for BMD-PC of the bilateral hips. There were no sig-
niﬁcant changes in the three T score stages between these three
groups.
The pretherapy mean eGFRs were not signiﬁcantly different in
the three groups (Table 4). The posttherapy mean eGFR in the R
Table 1
Adherence of the three groups.
R group D group T group p Post hocb
N 1000 477 138
Adherence 0.65 ± 0.16 0.98 ± 0.22 0.96 ± 0.32 <0.001a E group << T group/P group
Data are presented as mean ± standard deviation.
a p < 0.05 was considered statistically signiﬁcant after analysis of variance.
b Bonferroni correction was adopted while performing post hoc test.
Table 2
Demographic data.
T group D group R group p
N 67 33 34
Age (y)a 73.2 ± 11.0 69.1 ± 8.6 62.8 ± 8.4 <0.001c
BMI group (kg/m2)b d d d 0.057
Normal 33 (49.3) 9 (27.3) 16 (47.1)
Underweight 6 (9.0) 2(6.1) 0 (0.0)
Overweight 11 (16.4) 11 (33.3) 12 (35.3)
Obese 17 (25.4) 11 (33.3) 6 (17.6)
Previous vertebroplastyb 9 (13.4) 2 (6.1) 0 (0.0) 0.037c
Steroid userb 1 (1.5) 1 (3.0) 0 (0.0) 0.744
RAb 2 (3.0) 1 (3.0) 4 (11.8) 0.179
Hypertensionb 43 (64.2) 22 (66.7) 12 (35.3) 0.011c
Psychologic diseaseb 16 (23.9) 5 (15.2) 2 (5.9) 0.062
Heart diseaseb 22 (32.8) 8 (24.2) 6 (17.6) 0.266
DMb 18 (26.9) 11 (33.3) 6 (17.6) 0.334
Dialysisb 2 (3.0) 1 (3.0) 0 (0.0) 0.617
Other autoimmune diseaseb 4 (6.0) 1 (3.0) 0 (0.0) 0.439
FRAX(W/O BMD)a 11.7 ± 9.7 6.7 ± 5.3 4.5 ± 3.3 <0.001c
FRAX(W/I BMD)a 23.8 ± 11.6 18.1 ± 8.6 14.4 ± 6.7 <0.001c
Data are presented as n (%) or mean ± standard deviation.
BMD ¼ bone mineral density; BMI ¼ body mass index; DM ¼ diabetes mellitus;
FRAX ¼ the fracture risk assessment (being calculated from the site: http://www.
shef.ac.uk/FRAX/tool.jsp?lang¼cht based on Taiwan population data.);
RA ¼ rheumatoid arthritis.
a The p value was computed from analysis of variance.
b The p value was computed from Chi-square test.
c The p value < 0.05 was considered statistically signiﬁcant after test.
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(p ¼ 0.003). The posttherapy mean eGFRs in the T and D groups
showed mild but insigniﬁcant decreases compared with the pre-
therapy mean eGFRs.
There were no records of atypical fracture events or jaw osteo-
necrosis in these 1615 cases after 48 months of antiosteoporotic
treatment.4. Discussion
This is a retrospective study comparing BMD-PC and renal
function tests in postmenopausal women with osteoporosisTable 3
Absolute bone mineral density percentage change comparison between different groups
Result T group D group
N 67 33
BMD-PC(Spine)a 8.1 ± 5.8 12.1 ± 6.5
BMD-PC(Left Hip)a 9.6 ± 6.4 10.0 ± 7.7
BMD-PC(Right Hip)a 8.0 ± 6.5 10.4 ± 8.0
TTSb (PosttherapyePretherapy) d d
<¼0 19 (28.4) 6 (18.2)
0e0.5 16 (23.9) 10 (30.3)
>0.5 32 (47.8) 17 (51.5)
Data are presented as n (%) or mean ± standard deviation.
BMD-PC ¼ percentage change of bone mineral density; TTS ¼ total spine T score.
a The p value was computed from analysis of variance and Bonferroni correction was
b The p value was computed from Chi-square test.
c The p < 0.05 was considered statistically signiﬁcant after test.between thosewho received regular administration of raloxifene or
denosumab or transitioned from raloxifene to denosumab.
In general, BMD is an important predictor of bone strength and
the prevention of bone loss is an important mechanism in fracture
prevention. In this study, the BMD of the T group signiﬁcantly
increased compared with the R group in the spine and hip. The
critical factors appeared to be poorer adherence and the younger
age of those in the R group. Consistent with a previous study, we
found that patients treated with raloxifene were younger, were less
likely to receive a diagnosis of osteoporosis and have BMD
screening, and had lower rates of pretherapy fracture than those
treated with other antiosteoporotic agents [24]. We found that
denosumab can effectively increase BMD, whether it is used
initially or after transition from raloxifene. Previous studies
revealed good improvement in BMD after transition from
bisphosphonates to denosumab, and prior bisphosphonate usemay
decrease the improvement effect of denosumab [25]. Our study had
similar results in that raloxifene seemed to have some effects on the
antiosteoporotic activity of denosumab.
In our study, renal function remained good after raloxifene or
denosumab use. The R group had better renal function, possibly
because these patients were younger and had fewer comorbid
conditions such as vertebral fracture or hypertension before ther-
apy than those in the other groups. A previous study revealed that
participants on raloxifene had a slower yearly rate of increase in
creatinine and a signiﬁcantly slower yearly rate of decrease in the
eGFR compared with those in the placebo group over 3 years of
follow-up [22]. Raloxifene was associated with signiﬁcantly fewer
kidney-related adverse events compared with placebo and seemed
to be safe and renoprotective [26]. Previous study of denosumab
revealed that no adjustment is required in patients with renal
impairment because its metabolisation is via the reticuloendothe-
lial system and not through the kidneys [27]. Patients on both
medications showed no impairment in renal function after long-
term use. This result implies that these drugs may beneﬁt those
patients who have concomitant osteoporosis and chronic kidney
disease and those who have chronic illnesses, which are signiﬁcant
risk factors for chronic renal failure, such as uncontrolled diabetes
mellitus or hypertension..
R group p Post hoc
34
1.2 ± 5.8 <0.001c E group<T group<P group
1.2 ± 9.2 <0.001c E group<T group/P group





adopted while performing post hoc test.
Table 4
Pretherapy/posttherapy estimated glomerular ﬁltration rate of the three groups.
T group D group R group p Post hoc
N 67 33 34
Pre-eGFR(mL/min/1.73 m2)a 63.7 ± 27.3 66.4 ± 30.5 63.6 ± 13.9 0.861
Post-eGFR(mL/min/1.73 m2)a 58.2 ± 26.7 65.4 ± 23.4 76.3 ± 20.2 0.003b E group << T group/P group
Data are presented as mean ± standard deviation.
eGFR ¼ estimated glomerular ﬁltration rate.
a The p value was computed from analysis of variance and Bonferroni correction was adopted while performing post hoc test.
b The p value < 0.05 was considered statistically signiﬁcant after test.
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ical factor in the successful treatment of osteoporosis. A practical
advantage of denosumab over current therapies is its convenient
biannual administration, leading to better long-term adherence.
Although it has a disadvantage in terms of rapid BMD reduction and
putative fracture risk increase after discontinuation, rendering a
drug holiday prohibitive, good adherence and few complications
seem to make up for this deﬁcit in the treatment of osteoporosis
[28]. In this study we had satisfactory percentages of adherence in
the T and D groups, similar to the results of the BMD-PC. Raloxifene
has been considered an excellent drug for the treatment of osteo-
porosis and prevention of estrogen receptor-positive breast cancer
because it guarantees an excellent safety proﬁle on the endome-
trium and is good for those who have concomitant dyslipidemia.
Although it has resulted in less improvement in the BMD-PC and
turnover rate of bone-speciﬁc biomarkers, raloxifene appears to
prevent spine fracture [29]. However, weaker adherence can be a
problem in oral administration of raloxifene for elderly osteopo-
rotic women because of combination with many drugs for other
chronic diseases and poor memory about taking medications. In
our study, the R group, although younger, had signiﬁcantly poorer
adherence than the D and T groups. The selection of patients for
adequate osteoporotic treatment according to needs and charac-
teristics is an important issue for orthopedic surgeons.
The application of FRAX is practical as it is calculated by col-
lecting clinical risk factors to estimate the 10-year probability of the
risk of main and hip fractures. The estimate can be used alone or
with BMD to strengthen fracture risk prediction. In this study, the
FRAX value was signiﬁcantly lower in the T group, and the main
reason was the younger mean age in this group. FRAX uses data
derived from nine cohorts from all over the world, including cen-
ters in North America, Europe, Asia, and Australia. It has been
validated in 11 independent cohort studies with comparable
environmental factors [30]. The larger the sample applied in the
examination of the general relationship of each risk factor by age,
sex, duration of follow-up, and continuous variables (BMI and
BMD), the lower the relationship of risk related with the variable
itself. So the risk of publication bias is also eliminated by the use of
primary data. The validity of the clinical risk factors identiﬁed is
supported by the expected relationships between fracture risks and
BMD [31].
Limitations of this study include the small amount of data that
could be traced from a review of charts and the lack of analysis of
bone speciﬁc biomarker levels. The relatively small case numbers in
the transition group and denosumab group may have critical inﬂu-
ence on medical adherence. Compared with the other groups, pa-
tients in the R groupwere younger and had less comorbidity, such as
hypertension and spinal vertebral body compression fracture, which
is indicative of vertebroplasty. These factors may also contribute to
sequential BMD and eGFR changes. Future work such as regression
risk factor analysis on a greater number of patients can show their
inﬂuence on changes in bone density and renal function. Prospective
study of those who intend to transition from raloxifene todenosumab is also needed and more data related to serum bio-
markers of bone turnover rates should be collected from those who
receive regular treatment with raloxifene or denosumab.
In conclusion, patients who transitioned from raloxifene to
denosumab showed good adherence to treatment and signiﬁcant
improvements in the BMD of the spine and hip without a negative
inﬂuence on renal function. There were still some effects from the
previous use of raloxifene on increases in the BMD in the spine, but
more comprehensive study is needed to investigate this point.
Discussing the best antiosteoporotic treatment and the character-
istics of both drugs with patients is important for satisfactory re-
sults in the prevention of fractures.References
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